NeuroBo Pharmaceuticals Rebrands as MetaVia: Focusing on Cardiometabolic Disease Treatments

NeuroBo Pharmaceuticals Rebrands as MetaVia

NeuroBo Pharmaceuticals has rebranded as MetaVia. This change reflects the company’s shift from neurology to cardiometabolic disease treatments. The new name suggests a future-focused approach, where “Meta” means beyond and “Via” means through.

The rebranding follows NeuroBo’s merger with Gemphire in 2019. Originally, the company focused on Alzheimer’s disease and diabetic neuropathy treatments. Now, it concentrates on managing MASH (Metabolic Dysfunction-associated Steatotic Liver Disease) and obesity.

MetaVia will also change its Nasdaq ticker symbol to “MTV” and launch a new website, metaviatx.com. The company will introduce a new logo as part of this transition. There are no expected changes in management.

The timing coincides with important trial data releases. MetaVia is set to share results on its experimental drug, DA-1241. This drug targets G-Protein-Coupled Receptor 119 (GPR119) to treat MASH, with market potential in the billions. The company will also release data from DA-1726, which aims to treat obesity.

Hyung Heon Kim, president and CEO, stated that the name change marks a key step in their transition to develop therapies for cardiometabolic diseases.

According to the company’s third-quarter financial report, MetaVia has over $21 million in cash. This amount should fund operations for the next 12 months.